Clinical and Applied Thrombosis/Hemostasis (May 2023)

Preoperative Venous Thromboembolism Screening and Postoperative Selective Anticoagulant Therapy Effectively Prevents Postoperative Symptomatic Venous Thromboembolism in Gynecological Malignancies: A 15-Year, Single-Center Study

  • Nobutaka Tasaka MD,
  • Takeo Minaguchi MD, PhD,
  • Narushi Iwata MD,
  • Asuka Suzuki MD,
  • Kaoru Fujieda MD,
  • Asami Suto MD,
  • Hiroya Itagaki MD,
  • Ayumi Shikama MD, PhD,
  • Azusa Akiyama MD, PhD,
  • Sari Nakao MD, PhD,
  • Toyomi Satoh MD, PhD

DOI
https://doi.org/10.1177/10760296231178300
Journal volume & issue
Vol. 29

Abstract

Read online

The aim of this study was to determine which type of prophylaxis was effective for postoperative symptomatic venous thromboembolism (VTE) in patients with gynecological malignancies. A total of 1756 consecutive patients undergoing laparotomy as first-line treatment were included. In Period 1 (2004–2009), low-molecular weight heparin (LMWH) was not available for postoperative VTE prophylaxis, but available in after Period 2 (2009–2013). In Period 3 (2013–2020), patients with pretreatment VTE could switch from LMWH to direct oral anticoagulant (DOAC) as of 2015. Preoperative VTE was screened by measuring D-dimer, followed by venous ultrasound imaging, and computed tomography and/or perfusion lung scintigraphy. Postoperative symptomatic VTE occurred with an incidence of 2.8% by the measures without prophylactic LMWH administration in Period 1. The incidence of postoperative symptomatic VTE was 0.6% in Period 2 and 0.3% in Period 3, being significantly reduced compared with Period 1 ( P < .01 and < .0001). The incidences were not significantly different between Periods 2 and 3, but no patient switching to DOAC in Period 3 (n = 79) developed symptomatic VTE. Our preoperative VTE screening and postoperative selective LMWH administration were significantly preventive against postoperative symptomatic VTE.